05/02/2026
How could a biotech company explain their mRNA testing technology
for use as biomarkers in multiple human diseases?
Most go to the usual methods:
a PDF deck full of text,
a couple of scientific papers,
a list of bullet points,
maybe a dense slide in a pitch.
All valid. All scientific.
But none simple to grasp at a glance.
Here’s how we’ve explained it
to show that Destina Genomics has solved the real limitations holding back.
Current mRNA detection methods struggle with instability, low specificity, complex workflows and limited clinical scalability.
Destina Genomics overcomes these barriers through a novel chemical approach combining a stable tech buffer, DGL-Probes, SMART-Bases and peptide nucleic acids for more reliable .
We turned these elements into a visual narrative,
so scientists, clinicians and partners can actually see how it works
without sacrificing the science.
Because explaining biotech shouldn’t feel like decoding hieroglyphs.
It should feel like understanding what’s next.
